Voyager Therapeutics Inc
Company Profile
Business description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Contact
75 Hayden Avenue
LexingtonMA02421
USAT: +1 857 259-5340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
172
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,174.20 | 14.39 | -0.18% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,354.57 | 81.52 | -0.86% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |